His main research concerns Transplantation, Internal medicine, Surgery, Immunology and Hematopoietic stem cell transplantation. The various areas that Nicolaus Kröger examines in his Transplantation study include Leukemia, Stem cell, Myelodysplastic syndromes and Multiple myeloma. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.
His Surgery study combines topics in areas such as Hazard ratio and Confidence interval. His work in the fields of Immunotherapy, Myelofibrosis, Cancer/testis antigens and T cell overlaps with other areas such as Decitabine. His Hematopoietic stem cell transplantation research includes elements of Chemotherapy regimen, Acute leukemia, Intensive care medicine, Transplantation Conditioning and Risk factor.
Nicolaus Kröger spends much of his time researching Transplantation, Internal medicine, Hematopoietic stem cell transplantation, Oncology and Stem cell. His study in Transplantation is interdisciplinary in nature, drawing from both Immunology, Myelofibrosis, Bone marrow and Multiple myeloma. Nicolaus Kröger interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine.
As a part of the same scientific family, Nicolaus Kröger mostly works in the field of Hematopoietic stem cell transplantation, focusing on Leukemia and, on occasion, Myeloid. His Oncology research includes themes of Chemotherapy, Myeloid leukemia, Survival analysis, Chronic lymphocytic leukemia and Acute leukemia. In the field of Stem cell, his study on Haematopoiesis overlaps with subjects such as In patient.
His primary scientific interests are in Internal medicine, Transplantation, Oncology, Stem cell and Hematopoietic stem cell transplantation. His research investigates the link between Internal medicine and topics such as Gastroenterology that cross with problems in Cumulative incidence. His Transplantation study combines topics from a wide range of disciplines, such as Hematopoietic cell, Myeloid leukemia, Disease, Myelofibrosis and Acute leukemia.
Nicolaus Kröger combines subjects such as Haematopoiesis, Refractory, Regimen, Chronic lymphocytic leukemia and Multiple myeloma with his study of Oncology. The concepts of his Stem cell study are interwoven with issues in Idelalisib and Immune system. His Hematopoietic stem cell transplantation research is multidisciplinary, incorporating perspectives in Myelodysplastic syndromes, Immunology, Cohort study and Risk factor.
Nicolaus Kröger focuses on Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Disease. The study incorporates disciplines such as Myeloid, Myeloid leukemia, Stem cell, Hazard ratio and Myelofibrosis in addition to Transplantation. His Oncology research incorporates themes from Chronic lymphocytic leukemia, Hematopoietic cell and Chimeric antigen receptor, Cytokine release syndrome.
His study on Allogeneic hematopoietic stem cell transplant is often connected to Viral dynamics as part of broader study in Hematopoietic stem cell transplantation. His studies deal with areas such as Bone marrow and Intensive care medicine as well as Disease. Nicolaus Kröger has researched Cumulative incidence in several fields, including Gastroenterology, Refractory and Acute leukemia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kröger;Ernst Holler;Guido Kobbe;Martin Bornhäuser.
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti.
Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
ZiYi Lim;Ronald Brand;Rodrigo Martino;Anja van Biezen.
Journal of Clinical Oncology (2010)
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
Nicolaus Kröger;Herbert Gottfried Sayer;Rainer Schwerdtfeger;Michael Kiehl.
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Martin Bornhäuser;Joachim Kienast;Rudolf Trenschel;Andreas Burchert.
Lancet Oncology (2012)
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
Martin Kropff;Guido Bisping;Elke Schuck;Peter Liebisch.
British Journal of Haematology (2007)
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gösta Gahrton;Simona Iacobelli;Bo Björkstrand;Ute Hegenbart.
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
Martin Schmidt-Hieber;Myriam Labopin;Dietrich Beelen;Liisa Volin.
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid;Myriam Labopin;Arnon Nagler;Dietger Niederwieser.
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo De Witte;David Bowen;Marie Robin;Luca Malcovati.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: